"This isn't trivial. It's not copycat stuff," says Mike Kamarck, president of Merck & Co. Inc.'s three-year-old Merck BioVentures unit, about developing biosimilar drugs. It's clear to everyone in, or entering, the biosimilars game that creating biologic copies is more expensive and far more complicated than what’s required to make chemical generics. It also involves a whole new set of regulatory requirements – very fresh indeed in the US – which push up biosimilars' development costs and affect their market positioning.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?